Beijing Airdoc Technology Co. Ltd. Class H stock analysis
Want to see HK:2251 full AI Analyst Report?
Beijing Airdoc Technology Co. Ltd. Class H (2251) Stock Price & Analysis
2251 Stock Chart & Stats
- Day’s Range
- HKD 8.71 - HKD 8.88
- 52-Week Range
- HKD 6.95 - HKD 13.77
- Previous Close
- HKD 8.95
- Volume
- N/A
- Average Volume (3M)
- 91.06K
- Market Cap
- HKD 858.63M
- Enterprise Value
- HKD 363.09M
- Total Cash (Recent Filing)
- HKD 680.28M
- Total Debt (Recent Filing)
- HKD 26.04M
- Price to Earnings (P/E)
- ―
- Beta
- 0.88
- Next Earnings
- Apr 01, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Revenue growth recovered to 15.3% in 2025 after flat-to-down performance in 2024, indicating renewed commercial momentum. If sustained, stronger demand can expand the installed customer base, support operating leverage, and reinforce the company’s position in AI-enabled medical imaging.
Gross Margin Expansion
Gross margin expansion to roughly 66% from 55% shows materially improved unit economics and suggests the company is retaining more value from each sale. This provides a stronger foundation for future operating leverage and eventual profitability if revenue momentum continues.
Low Financial Leverage
Very low leverage gives the company financial flexibility and reduces refinancing risk while it invests in growth and works toward profitability. A conservatively capitalized balance sheet also offers greater resilience if operating conditions weaken or cash conversion remains uneven.
Bears Say
Persistent Losses
The company remains loss-making despite improved revenue and gross margin, showing that stronger unit economics have not yet translated into sustainable operating earnings. Continued losses can restrict internally funded investment, delay self-financing growth, and keep profitability dependent on further execution improvements.
Unreliable Cash Generation
Negative operating and free cash flow in 2025 indicates that reported business activity is not yet converting reliably into cash. The multi-year volatility in cash conversion increases execution risk and may constrain the company’s ability to fund expansion without using its balance-sheet resources.
Negative Returns On Equity
Negative ROE across every year shown indicates that shareholder capital has not yet generated positive returns. This reflects the company’s ongoing losses and limits balance-sheet efficiency, making sustained improvement in operating profitability essential for creating durable shareholder value.
Beijing Airdoc Technology Co. Ltd. Class H News
2251 FAQ
What was Beijing Airdoc Technology Co. Ltd. Class H’s price range in the past 12 months?
What is Beijing Airdoc Technology Co. Ltd. Class H’s market cap?
When is Beijing Airdoc Technology Co. Ltd. Class H’s upcoming earnings report date?
How were Beijing Airdoc Technology Co. Ltd. Class H’s earnings last quarter?
Is Beijing Airdoc Technology Co. Ltd. Class H overvalued?
Does Beijing Airdoc Technology Co. Ltd. Class H pay dividends?
What is Beijing Airdoc Technology Co. Ltd. Class H’s EPS estimate?
How many shares outstanding does Beijing Airdoc Technology Co. Ltd. Class H have?
What happened to Beijing Airdoc Technology Co. Ltd. Class H’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Beijing Airdoc Technology Co. Ltd. Class H?
What is the TipRanks Smart Score and how is it calculated?
Beijing Airdoc Technology Co. Ltd. Class H Stock Smart Score
Company Description
Beijing Airdoc Technology Co. Ltd. Class H
Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Da Lei Zhang
- Employees
- 155
- Website
- www.airdoc.com
- Address
- Building 2, A2 Yard, Beijing, BE, 100089, CN
Beijing Airdoc Technology Co. Ltd. Class H (2251) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 4 | 14 |
| Technical Analysis | 4 | 4 | 2 |
| Moving Averages | 0 | 0 | 12 |
